SEC Form 4 · accession 0001140361-17-021014
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Galligan
Officer — Chief Financial Officer
Period of report
May 15, 2017
Accepted (ET)
May 16, 2017 · 4:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 15, 2017 | M | 7,500 | $3.60 | A | 19,333 | D | |
| Common StockF3,F1 | May 15, 2017 | S | 3,496 | $74.6928 | D | 15,837 | D | |
| Common StockF4,F1 | May 15, 2017 | S | 2,698 | $75.5472 | D | 13,139 | D | |
| Common StockF5,F1 | May 15, 2017 | S | 1,306 | $76.4027 | D | 11,833 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $3.60 | May 15, 2017 | M | 7,500 | D | — | Sep 28, 2021 | Common Stock | 7,500 | 44,546 | D |
Explanation of responses
- F1Includes 6,833 restricted stock units.
- F2The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $73.96 to $74.94, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.02 to $75.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $76.02 to $76.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6100% of the shares subject to the option are fully vested and exercisable.